Fall River, MA (PRWEB) May 21, 2010
Jeffrey Morrill, CEO of NuOrtho Surgical, Inc. of Fall River, Massachusetts, is pleased to announce that Eric E. Ray has joined the company as Director of Sales for the United States.
“Eric is a great addition to our team. As a veteran medical device sales and marketing executive with 14 years of orthopedic device knowledge, he has proven experience in launching new products and growing sales at both start-up firms and large corporations. Eric’s talents, leadership and dedication will provide the qualities needed to organize our sales, marketing, professional education and customer service efforts, something he has done before in his career, and we expect him to perform at a high level in his role for NuOrtho Surgical, Inc.,” stated Morrill.
Mr. Ray gained much of his experience at Johnson & Johnson’s Depuy, a $13 billion medical device division, where he served in various sales, management and marketing roles for eight years. While at DePuy, Mr. Ray managed more than $50 million in products and commercially launched several products overseas. He also served as National Sales & Marketing Manager for DePuy Mitek in Australia, providing the initiatives for change and capitalization on various sports medicine and joint ventures.
Mr. Ray has brought a great network of industry sales contacts to NuOrtho and has already begun signing and entering into contract negotiations with a variety of strategic key agent groups throughout the country. “Eric has made an immediate impact in executing our go-to- market plans,” stated Morrill.
“NuOrtho’s unique product line provides an opportunity to improve the surgical outcome for surgeons and the active Baby Boomer generation. NuOrtho is a great company, and it will be a pleasure to lead their sales efforts,” stated Ray.
NuOrtho Surgical is focused on the manufacture of surgical instruments that enable Tissue Preservation™ in the orthopedic arena to improve patient outcomes. NuOrtho has three primary product platforms for preserving healthy tissue to sustain long-term mobility. These platforms include Soft Tissue Treatment, Agent Delivery and Bone Fusion. NuOrtho’s first product launch will be Ceruleau™, a revolutionary product for soft tissue treatment in knee procedures for cartilage. The company has a growing patent portfolio, as they added another one recently, providing significant business opportunities. For further information visit http://www.nuortho.com.